Latest Options News

Synlait Milk Limited has reported a significant half-year loss driven by manufacturing setbacks and market pressures, alongside a strategic recovery roadmap focused on asset sales and operational overhaul.

WA Kaolin Limited has announced a $34.9 million recapitalisation plan involving a non-renounceable entitlement issue and debt conversion to strengthen its balance sheet and fund operational improvements at its Wickepin kaolin project.

Insignia Financial has secured a crucial regulatory approval from APRA, advancing the proposed acquisition by Daintree BidCo. The deal now moves closer to a shareholder vote scheduled for mid-April.

EBOS Group Limited has updated its interim dividend details for the six months ending December 2025, confirming a fully franked ordinary dividend and a supplementary dividend, alongside a Dividend Reinvestment Plan offering a 2% discount.

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

Chariot Resources has raised A$2.1 million through a share placement, attracting institutional and sophisticated investors to back its expanding lithium projects in the US and Nigeria. The placement includes free attaching options, pending shareholder approval.

Clara Resources has agreed to sell its Kildanga nickel-cobalt project for up to $1.75 million, marking a strategic shift to focus on its Mareeba gold exploration in Queensland.

Vintage Energy has launched a $2.1 million equity entitlement offer to fund drilling two new gas wells, supported by a South Australian government grant, and to advance oil exploration in the Cooper Basin.

Sequoia Financial Group faces a pivotal shift as HUB24 stops accepting new business from its InterPrac Financial Planning advisers, prompting a strategic transition for the company’s adviser network.

Key Petroleum Ltd has completed a modest 3% share placement but will not proceed with the remaining 13%, leaving questions over its funding strategy.

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

TMK Energy has raised $6 million in a heavily oversubscribed placement led by coal seam gas experts, aiming to accelerate drilling and commercialisation at its Gurvantes XXXV project.